RxDoctor Payments Data

Shiva Mahinrad, MD

Internal Medicine · Fleming Island, FLNPI 1922093095

Payments from drug & device makers

$2,861in general payments, 2019–2025

Across 145 payments — averaging $19.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$598
  • AstraZeneca$497
  • AbbVie$257
  • Lilly USA, LLC$206
  • GSK$190
  • Merck$178
  • plus $936 from 21 others

What the payments were for

  • Food & beverage$2,861100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,861 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$94,542
Medicare patients
284
Services billed
961

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide17$31,121
OzempicSemaglutide22$27,027
JardianceEmpagliflozin16$19,770
JanuviaSitagliptin Phosphate24$15,189
EliquisApixaban17$12,631
Atorvastatin Calcium127$1,326
Eplerenone13$1,171
Rosuvastatin Calcium104$1,097
Amlodipine Besylate150$886
Losartan Potassium98$836
Metoprolol Succinate61$815
Famotidine66$785
Bupropion XlBupropion Hcl22$702
Diclofenac Sodium20$691
Albuterol Sulfate HfaAlbuterol Sulfate29$650

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$206$31,12117 claims
Novo NordiskOzempic$598$27,02722 claims
Boehringer IngelheimJardiance$121$19,77016 claims
MerckJanuvia$178$15,18924 claims
PfizerEliquis$160$12,63117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Fleming Island

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →